Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.
Cooper Companies beats Q2 EPS and sales estimates as CooperVision and CooperSurgical hit record revenues, even with a GAAP loss from recall litigation.